Barclays’s BridgeBio Pharma BBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $53.2M | Buy |
714,423
+290,535
| +69% | +$20.3M | 0.01% | 710 |
|
|
2026
Q1 | $31.5M | Sell |
423,888
-198,687
| -32% | -$14.4M | 0.01% | 912 |
|
|
2025
Q4 | $47.6M | Sell |
622,575
-96,873
| -13% | -$6.36M | 0.01% | 801 |
|
|
2025
Q3 | $37.4M | Sell |
719,448
-214,064
| -23% | -$10.4M | 0.01% | 906 |
|
|
2025
Q2 | $40.3M | Buy |
933,512
+544,674
| +140% | +$19.8M | 0.01% | 802 |
|
|
2025
Q1 | $13.4M | Sell |
388,838
-58,672
| -13% | -$1.98M | ﹤0.01% | 1226 |
|
|
2024
Q4 | $12.3M | Sell |
447,510
-97,498
| -18% | -$2.52M | ﹤0.01% | 1425 |
|
|
2024
Q3 | $13.9M | Buy |
545,008
+131,743
| +32% | +$3.46M | ﹤0.01% | 1260 |
|
|
2024
Q2 | $10.5M | Buy |
413,265
+8,097
| +2% | +$221K | ﹤0.01% | 1170 |
|
|
2024
Q1 | $12.5M | Sell |
405,168
-336,870
| -45% | -$11.5M | ﹤0.01% | 1241 |
|
|
2023
Q4 | $30M | Buy |
742,038
+260,598
| +54% | +$7.83M | 0.01% | 889 |
|
|
2023
Q3 | $12.7M | Sell |
481,440
-107,724
| -18% | -$3.06M | 0.01% | 897 |
|
|
2023
Q2 | $10.1M | Sell |
589,164
-81,715
| -12% | -$1.23M | 0.01% | 984 |
|
|
2023
Q1 | $11.1M | Sell |
670,879
-531,006
| -44% | -$6.19M | 0.01% | 1114 |
|
|
2022
Q4 | $9.16M | Buy |
1,201,885
+875,468
| +268% | +$8.38M | ﹤0.01% | 1246 |
|
|
2022
Q3 | $3.24M | Buy |
326,417
+296,979
| +1,009% | +$3.09M | ﹤0.01% | 1424 |
|
|
2022
Q2 | $268K | Sell |
29,438
-13,148
| -31% | -$110K | ﹤0.01% | 3270 |
|
|
2022
Q1 | $432K | Sell |
42,586
-151,488
| -78% | -$1.55M | ﹤0.01% | 2998 |
|
|
2021
Q4 | $3.24M | Buy |
194,074
+104,508
| +117% | +$4.42M | ﹤0.01% | 2035 |
|
|
2021
Q3 | $4.2M | Buy |
89,566
+26,546
| +42% | +$1.42M | ﹤0.01% | 1746 |
|
|
2021
Q2 | $3.84M | Sell |
63,020
-37,199
| -37% | -$2.12M | ﹤0.01% | 1752 |
|
|
2021
Q1 | $6.17M | Buy |
100,219
+63,771
| +175% | +$4.17M | ﹤0.01% | 1358 |
|
|
2020
Q4 | $2.59M | Buy |
36,448
+3,076
| +9% | +$148K | ﹤0.01% | 2035 |
|
|
2020
Q3 | $1.25M | Sell |
33,372
-12,116
| -27% | -$381K | ﹤0.01% | 2494 |
|
|
2020
Q2 | $1.48M | Buy |
45,488
+16,124
| +55% | +$491K | ﹤0.01% | 2395 |
|
|
2020
Q1 | $851K | Buy |
29,364
+3,230
| +12% | +$100K | ﹤0.01% | 3117 |
|
|
2019
Q4 | $916K | Buy |
26,134
+12,431
| +91% | +$345K | ﹤0.01% | 3753 |
|
|
2019
Q3 | $294K | Sell |
13,703
-3,631
| -21% | -$100K | ﹤0.01% | 4672 |
|
|
2019
Q2 | $467K | Buy |
+17,334
| New | +$473K | ﹤0.01% | 4375 |
|
Other funds holding BBIO
JT
KKRC
FCM
ACM
Barclays's BBIO Position: Q2 2026 in Review
Barclays increased its BridgeBio Pharma (BBIO) stake by 69% in Q2 2026, buying an estimated $20.3M and bringing the position to 714,423 shares worth $53.2M. The position accounts for 0.01% of the portfolio, ranked #710.
Barclays first reported a position in BBIO in Q2 2019 and has held it in 29 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.
- Barclays held 714,423 shares of BridgeBio Pharma worth $53.2M as of Q2 2026.
- Barclays bought 290,535 BridgeBio Pharma shares in Q2 2026, an estimated $20.3M.
- BridgeBio Pharma made up 0.01% of Barclays's portfolio in Q2 2026, its #710 holding.
- Barclays first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 29 quarters since.
- 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.